Crosstalk in extrahepatic and hepatic system in NAFLD / NASH
Liver International · 2024
DOI: 10.1111/liv.15967 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, 2024. Verfasst von Yiliang Duan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, Ch…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Kupffer Cells, Liver, Hepatic Stellate Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 181 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Non‐alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease globally. Non‐alcoholic steatohepatitis (NASH) represents an extremely progressive form of NAFLD, which, without timely intervention, may progress to cirrhosis or hepatocellular carcinoma. Presently, a definitive comprehension of the pathogenesis of NAFLD/NASH eludes us, and pharmacological interventions targeting NASH specifically remain constrained. The aetiology of NAFLD encompasses a myriad of external factors including environmental influences, dietary habits and gender disparities. More significantly, inter‐organ and cellular interactions within the human body play a role in the development or regression of the disease. In this review, we categorize the influences affecting NAFLD both intra‐ and extrahepatically, elaborating meticulously on the mechanisms governing the onset and progression of NAFLD/NASH. This exploration delves into progress in aetiology and promising therapeutic targets. As a metabolic disorder, the development of NAFLD involves complexities related to nutrient metabolism, liver‐gut axis interactions and insulin resistance, among other regulatory functions of extraneous organs. It further encompasses intra‐hepatic interactions among hepatic cells, Kupffer cells (KCs) and hepatic stellate cells (HSCs). A comprehensive understanding of the pathogenesis of NAFLD/NASH from a macroscopic standpoint is instrumental in the formulation of future therapies for NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
- The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, China.
- Jiangsu Institute for Food and Drug Control, NMPA Key Laboratory for Impurity Profile of Chemical Drugs, Nanjing, Jiangsu, China.
ORCID-Profile: Jun Yin
Förderung
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Key R&D Program of Xinjiang Uygur Autonomous Region
- Innovation Team of the "Double-First Class" Disciplines
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Duan, Y., Yang, Y., Zhao, S., Bai, Y., Yao, W., Gao, X., & Yin, J. (2024). Crosstalk in extrahepatic and hepatic system in NAFLD / NASH. Liver International. https://doi.org/10.1111/liv.15967
Vancouver
Duan Y, Yang Y, Zhao S, Bai Y, Yao W, Gao X, et al. Crosstalk in extrahepatic and hepatic system in NAFLD / NASH. Liver International. 2024. doi:10.1111/liv.15967
BibTeX
@article{Duan2024,
author = {Duan, Yiliang and Yang, Yan and Zhao, Shuqiang and Bai, Yuesong and Yao, Wenbing and Gao, Xiangdong and Yin, Jun},
title = {Crosstalk in extrahepatic and hepatic system in NAFLD / NASH},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15967}
}
EUVIMED